India's Drug Controller General of India approved Takeda Pharmaceutical's dengue vaccine, Qdenga, for public use on June 13, 2024 [1, 2].
The approval marks a significant shift in the country's public health strategy to reduce hospital pressure and manage seasonal spikes of the virus [2, 3].
Qdenga is the first dengue vaccine cleared for use in India [1, 3]. The regulator approved the vaccine for individuals between the ages of four and 60 years [1]. To achieve full protection, the dosing schedule requires two doses administered zero and six months apart [2].
"The approval of Qdenga will be a game-changer in our fight against dengue," said Dr. Randeep Guleria, Director General of the ICMR [1].
Takeda Pharmaceutical plans to introduce the vaccine in phases. Hiroshi Tanaka, a Takeda spokesperson, said the vaccine is safe for the approved age group [2].
Despite the approval, some health observers have noted risks associated with dengue vaccinations. Reports from Brazil indicated two people died during a separate dengue-vaccine campaign [1]. While Takeda officials maintain that Qdenga is safe and should be introduced without restrictions, some reports suggest these international events warrant caution during the Indian rollout [1, 2].
"This marks India's first home-grown dengue vaccine approval," said health analyst Priya Sharma [3].
The vaccine aims to strengthen the overall response to a disease that frequently overwhelms urban healthcare infrastructure during monsoon seasons [2, 3].
“"The approval of Qdenga will be a game-changer in our fight against dengue,"”
The introduction of Qdenga provides India with its first clinical tool to proactively reduce dengue morbidity. However, the contrast between Takeda's safety assurances and the reported fatalities in Brazil's separate campaign highlights the ongoing challenge of vaccine safety monitoring in diverse populations. The phased rollout will likely determine if the vaccine can effectively lower the burden on the public health system during peak transmission periods.
